ZA200101186B - Phenyl xanthine derivatives. - Google Patents
Phenyl xanthine derivatives. Download PDFInfo
- Publication number
- ZA200101186B ZA200101186B ZA200101186A ZA200101186A ZA200101186B ZA 200101186 B ZA200101186 B ZA 200101186B ZA 200101186 A ZA200101186 A ZA 200101186A ZA 200101186 A ZA200101186 A ZA 200101186A ZA 200101186 B ZA200101186 B ZA 200101186B
- Authority
- ZA
- South Africa
- Prior art keywords
- purin
- dioxo
- bis
- tetrahydro
- methyl ether
- Prior art date
Links
- ACCCXSZCOGNLFL-UHFFFAOYSA-N 8-phenyl-3,7-dihydropurine-2,6-dione Chemical class N1C=2C(=O)NC(=O)NC=2N=C1C1=CC=CC=C1 ACCCXSZCOGNLFL-UHFFFAOYSA-N 0.000 title description 2
- 229920000847 nonoxynol Polymers 0.000 claims description 155
- 150000001875 compounds Chemical class 0.000 claims description 142
- WGKYSFRFMQHMOF-UHFFFAOYSA-N 3-bromo-5-methylpyridine-2-carbonitrile Chemical compound CC1=CN=C(C#N)C(Br)=C1 WGKYSFRFMQHMOF-UHFFFAOYSA-N 0.000 claims description 132
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 127
- 235000013985 cinnamic acid Nutrition 0.000 claims description 127
- 229930016911 cinnamic acid Natural products 0.000 claims description 127
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 127
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 125
- 239000000203 mixture Substances 0.000 claims description 67
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 65
- 239000002253 acid Substances 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 54
- -1 said cycloalky! Chemical group 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 150000002148 esters Chemical class 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 29
- 150000001408 amides Chemical class 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 208000028169 periodontal disease Diseases 0.000 claims description 17
- 125000003107 substituted aryl group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 125000004544 purin-8-yl group Chemical group N1=CN=C2N=C(NC2=C1)* 0.000 claims description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 208000026278 immune system disease Diseases 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 230000004968 inflammatory condition Effects 0.000 claims description 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 7
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- IALGNTFRVIHOSL-FLNCGGNMSA-N (E)-3-[4-[1,3-bis(cyclohexylmethyl)-2,6-dioxo-7-prop-2-ynylpurin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C(N1CC#C)=NC2=C1C(=O)N(CC1CCCCC1)C(=O)N2CC1CCCCC1 IALGNTFRVIHOSL-FLNCGGNMSA-N 0.000 claims description 4
- XAHJEPPRQOCLMF-KLSJZZFUSA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)C)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)C)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O XAHJEPPRQOCLMF-KLSJZZFUSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000008506 pathogenesis Effects 0.000 claims description 4
- ZBIJJUUYDGLZEB-ZUQRMPMESA-N (E)-3-[4-[1,3-bis(2-cyclohexylethyl)-2,6-dioxo-7H-purin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CCN1C(N(C=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)CCC1CCCCC1)=O ZBIJJUUYDGLZEB-ZUQRMPMESA-N 0.000 claims description 3
- OJCFEGKCRWEVSN-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO OJCFEGKCRWEVSN-UHFFFAOYSA-N 0.000 claims description 3
- YCWPSAYEVQPQTA-NBYYMMLRSA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C(CC)C1CC(CCC1)CN1C(NC=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)=O Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C(CC)C1CC(CCC1)CN1C(NC=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)=O YCWPSAYEVQPQTA-NBYYMMLRSA-N 0.000 claims description 3
- SRPKLPVNEDFBCF-GOSREXKOSA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.c1cc(/C=C/C(=O)O)ccc1-c1nc2n(CC3CCCCC3)c(=O)n(CC3CCCCC3)c(=O)c2n1CC(=O)c1ccccc1 Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.c1cc(/C=C/C(=O)O)ccc1-c1nc2n(CC3CCCCC3)c(=O)n(CC3CCCCC3)c(=O)c2n1CC(=O)c1ccccc1 SRPKLPVNEDFBCF-GOSREXKOSA-N 0.000 claims description 3
- DBASZNTZKLRXSI-ZUQRMPMESA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O DBASZNTZKLRXSI-ZUQRMPMESA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- YSTGKSQLLQVZGV-NBYYMMLRSA-N (E)-3-[4-[1,3-bis(cyclobutylmethyl)-2,6-dioxo-7H-purin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C1=NC(C(N(CC2CCC2)C(=O)N2CC3CCC3)=O)=C2N1 YSTGKSQLLQVZGV-NBYYMMLRSA-N 0.000 claims description 2
- OXVWIJJNMKEUMZ-ZUQRMPMESA-N (E)-3-[4-[1,3-bis(cyclohexylmethyl)-2,6-dioxo-7H-purin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C1=NC(C(N(CC2CCCCC2)C(=O)N2CC3CCCCC3)=O)=C2N1 OXVWIJJNMKEUMZ-ZUQRMPMESA-N 0.000 claims description 2
- PHPTYNIVTRERGL-CCEZHUSRSA-N (e)-3-[3-[1,3-bis(cyclohexylmethyl)-2,6-dioxo-7h-purin-8-yl]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(C=2NC3=C(C(N(CC4CCCCC4)C(=O)N3CC3CCCCC3)=O)N=2)=C1 PHPTYNIVTRERGL-CCEZHUSRSA-N 0.000 claims description 2
- DANLZOIRUUHIIX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C1=CC=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F DANLZOIRUUHIIX-UHFFFAOYSA-N 0.000 claims description 2
- XBROICKYXLMJHU-FJUODKGNSA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.FC1=CC=C(CN2C(N(C=3NC(=NC3C2=O)C2=CC=C(/C=C/C(=O)O)C=C2)CC2=CC=C(C=C2)F)=O)C=C1 Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.FC1=CC=C(CN2C(N(C=3NC(=NC3C2=O)C2=CC=C(/C=C/C(=O)O)C=C2)CC2=CC=C(C=C2)F)=O)C=C1 XBROICKYXLMJHU-FJUODKGNSA-N 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 208000037816 tissue injury Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 21
- ATEQPBZVVKMNFL-FLNCGGNMSA-N (E)-3-[4-[1,3-bis(cyclohexylmethyl)-7-(2-methylprop-2-enyl)-2,6-dioxopurin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.O=C1N(CC2CCCCC2)C(=O)C=2N(CC(=C)C)C(C=3C=CC(\C=C\C(O)=O)=CC=3)=NC=2N1CC1CCCCC1 ATEQPBZVVKMNFL-FLNCGGNMSA-N 0.000 claims 3
- OESFJCZLLCTOJF-UHFFFAOYSA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)CC1=CC=CC=C1)C1=CC=C(C(=O)O)C=C1)CC1CCCCC1)=O Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)CC1=CC=CC=C1)C1=CC=C(C(=O)O)C=C1)CC1CCCCC1)=O OESFJCZLLCTOJF-UHFFFAOYSA-N 0.000 claims 3
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 claims 3
- VDMRAQAKUUUKET-FLNCGGNMSA-N (E)-3-[4-[1,3-bis(cycloheptylmethyl)-2,6-dioxo-7H-purin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCCC1)CN1C(N(C=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCCC1)=O VDMRAQAKUUUKET-FLNCGGNMSA-N 0.000 claims 2
- YZFOJTPUQQCGBO-FLNCGGNMSA-N (E)-3-[4-[1,3-bis(cyclohexylmethyl)-7-ethyl-2,6-dioxopurin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.O=C1N(CC2CCCCC2)C(=O)C=2N(CC)C(C=3C=CC(\C=C\C(O)=O)=CC=3)=NC=2N1CC1CCCCC1 YZFOJTPUQQCGBO-FLNCGGNMSA-N 0.000 claims 2
- HLPJNSYWIJBWEJ-GOSREXKOSA-N (E)-3-[4-[7-benzyl-1,3-bis(cyclohexylmethyl)-2,6-dioxopurin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CCCCC1)C(=O)N2CC1CCCCC1 HLPJNSYWIJBWEJ-GOSREXKOSA-N 0.000 claims 2
- AGWKUHGLWHMYTG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCO AGWKUHGLWHMYTG-UHFFFAOYSA-N 0.000 claims 2
- PQYIFXMUYXVPMV-FLNCGGNMSA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)CC(=O)OCC)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)CC(=O)OCC)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O PQYIFXMUYXVPMV-FLNCGGNMSA-N 0.000 claims 2
- DNMZJIGSDQVGSA-UHFFFAOYSA-N methoxymethane;hydrochloride Chemical compound Cl.COC DNMZJIGSDQVGSA-UHFFFAOYSA-N 0.000 claims 2
- MDKAVMDZSXHFFF-HCUGZAAXSA-N (E)-3-[4-[1,3-bis(2-methylpropyl)-2,6-dioxo-7H-purin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.CC(CN1C(N(C=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)CC(C)C)=O)C MDKAVMDZSXHFFF-HCUGZAAXSA-N 0.000 claims 1
- AEAYZIMASHXPSM-FLNCGGNMSA-N (E)-3-[4-[1,3-bis(cyclohexylmethyl)-2,6-dioxo-7-propylpurin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)CCC)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O AEAYZIMASHXPSM-FLNCGGNMSA-N 0.000 claims 1
- LVQICOYOIOOCLP-ZUQRMPMESA-N (E)-3-[4-[1,3-bis(cyclohexylmethyl)-2,6-dioxo-7H-purin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound C(CCCCCCCCCCC)OCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O LVQICOYOIOOCLP-ZUQRMPMESA-N 0.000 claims 1
- ZEROKSIPULJJLY-KLSJZZFUSA-N (E)-3-[4-[1,3-bis(cyclohexylmethyl)-7-methyl-2,6-dioxopurin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)C)C1=CC=C(/C=C/C(=O)O)C=C1)CC1CCCCC1)=O ZEROKSIPULJJLY-KLSJZZFUSA-N 0.000 claims 1
- LKZNIQKJUAZOJG-KLSJZZFUSA-N (E)-3-[4-[1,3-bis(cyclohexylmethyl)-7-methyl-2,6-dioxopurin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCO.O=C1N(CC2CCCCC2)C(=O)C=2N(C)C(C=3C=CC(\C=C\C(O)=O)=CC=3)=NC=2N1CC1CCCCC1 LKZNIQKJUAZOJG-KLSJZZFUSA-N 0.000 claims 1
- MIAAVIRGNXXYRD-NBYYMMLRSA-N (E)-3-[4-[1-(cyclohexylmethyl)-7-methyl-2,6-dioxo-3H-purin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1CC(CCC1)CN1C(NC=2N=C(N(C2C1=O)C)C1=CC=C(/C=C/C(=O)O)C=C1)=O MIAAVIRGNXXYRD-NBYYMMLRSA-N 0.000 claims 1
- UTMCXVIPFWOWAG-UNGNXWFZSA-N (E)-3-[5-[1,3-bis(cyclohexylmethyl)-2,6-dioxo-7H-purin-8-yl]thiophen-2-yl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(NC2C1=O)C1=CC=C(S1)/C=C/C(=O)O)CC1CCCCC1)=O UTMCXVIPFWOWAG-UNGNXWFZSA-N 0.000 claims 1
- PPYQHXUMMPHXFC-UHFFFAOYSA-N 1,3-bis(cyclohexylmethyl)-8-[4-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxymethyl]phenyl]-7h-purine-2,6-dione Chemical compound C1=CC(COCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=CC=C1C(N1)=NC2=C1C(=O)N(CC1CCCCC1)C(=O)N2CC1CCCCC1 PPYQHXUMMPHXFC-UHFFFAOYSA-N 0.000 claims 1
- FJDUHTBWYFWGJM-UHFFFAOYSA-N 4-[1,3-bis(cyclohexylmethyl)-7-methyl-2,6-dioxopurin-8-yl]benzoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CN1C(N(C=2N=C(N(C2C1=O)C)C1=CC=C(C(=O)O)C=C1)CC1CCCCC1)=O FJDUHTBWYFWGJM-UHFFFAOYSA-N 0.000 claims 1
- QIHONRNIAWGJPL-JHGYPSGKSA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CCCCN1C(NC=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)=O Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)CCCCN1C(NC=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)=O QIHONRNIAWGJPL-JHGYPSGKSA-N 0.000 claims 1
- BFMYHGHIDJNQAX-ZUQRMPMESA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)N1C(N(C=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)C1CCCCC1)=O Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1(CCCCC1)N1C(N(C=2NC(=NC2C1=O)C1=CC=C(/C=C/C(=O)O)C=C1)C1CCCCC1)=O BFMYHGHIDJNQAX-ZUQRMPMESA-N 0.000 claims 1
- CTADGRFDLKZNKA-ZUQRMPMESA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C(N1CC#N)=NC2=C1C(=O)N(CC1CCCCC1)C(=O)N2CC1CCCCC1 Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C(N1CC#N)=NC2=C1C(=O)N(CC1CCCCC1)C(=O)N2CC1CCCCC1 CTADGRFDLKZNKA-ZUQRMPMESA-N 0.000 claims 1
- CLUAKXQDMMMMOS-JHGYPSGKSA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C1=NC(C(N(CC2CCCC2)C(=O)N2CC3CCCC3)=O)=C2N1 Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C1=NC(C(N(CC2CCCC2)C(=O)N2CC3CCCC3)=O)=C2N1 CLUAKXQDMMMMOS-JHGYPSGKSA-N 0.000 claims 1
- JOHVQYKKMGGVMA-ZUQRMPMESA-N COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C1=NC(C(N(CCC=2C=CC=CC=2)C(=O)N2CCC=3C=CC=CC=3)=O)=C2N1 Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C1=NC(C(N(CCC=2C=CC=CC=2)C(=O)N2CCC=3C=CC=CC=3)=O)=C2N1 JOHVQYKKMGGVMA-ZUQRMPMESA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 238000010265 fast atom bombardment Methods 0.000 description 38
- 239000000243 solution Substances 0.000 description 28
- 238000009472 formulation Methods 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 206010040070 Septic Shock Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000011321 prophylaxis Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000036303 septic shock Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229960001701 chloroform Drugs 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- GPTPPLBWOXHYIO-UHFFFAOYSA-N 5,6-diamino-1,3-bis(cyclohexylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC2CCCCC2)C(N)=C(N)C(=O)N1CC1CCCCC1 GPTPPLBWOXHYIO-UHFFFAOYSA-N 0.000 description 3
- VRIFEJRSXKSEPT-UHFFFAOYSA-N 6-amino-1,3-bis(cyclohexylmethyl)-5-nitrosopyrimidine-2,4-dione Chemical compound O=C1N(CC2CCCCC2)C(N)=C(N=O)C(=O)N1CC1CCCCC1 VRIFEJRSXKSEPT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 3
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- VVHAVLIDQNWEKF-UHFFFAOYSA-N nonaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO VVHAVLIDQNWEKF-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- VVBQKDDPSXBMMZ-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-phenylmethoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCC1=CC=CC=C1 VVBQKDDPSXBMMZ-UHFFFAOYSA-N 0.000 description 2
- LSYWOSOCTVKSLX-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-(2-amino-2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COC(N)COCCOCCOCCOCCOCCOCCOCCOCCO LSYWOSOCTVKSLX-UHFFFAOYSA-N 0.000 description 2
- AAFALUZRMOLETN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxymethylbenzene Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCC1=CC=CC=C1 AAFALUZRMOLETN-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 208000019836 digestive system infectious disease Diseases 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011872 intimate mixture Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- VRZJGNXBSRQZGM-UHFFFAOYSA-N xanthine-8-carboxylic acid Chemical class N1C(=O)NC(=O)C2=C1N=C(C(=O)O)N2 VRZJGNXBSRQZGM-UHFFFAOYSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- ACGQHWSXTHERRV-OAZHBLANSA-N (E)-3-[4-[1,3-bis(2-bicyclo[2.2.1]heptanylmethyl)-2,6-dioxo-7H-purin-8-yl]phenyl]prop-2-enoic acid 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCO.C1=CC(/C=C/C(=O)O)=CC=C1C1=NC(C(N(CC2C3CCC(C3)C2)C(=O)N2CC3C4CCC(C4)C3)=O)=C2N1 ACGQHWSXTHERRV-OAZHBLANSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- OXNQXTMFDUOHBS-CCEZHUSRSA-N (e)-3-[3-[1,3-bis(cyclohexylmethyl)-2,6-dioxo-7h-purin-8-yl]phenyl]prop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC(C=2NC=3C(=O)N(CC4CCCCC4)C(=O)N(CC4CCCCC4)C=3N=2)=C1 OXNQXTMFDUOHBS-CCEZHUSRSA-N 0.000 description 1
- LERWZBXJAOSNBN-DTQAZKPQSA-N (e)-3-[4-[1,3-bis(cyclohexylmethyl)-2,6-dioxo-7h-purin-8-yl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C1=NC(C(N(CC2CCCCC2)C(=O)N2CC3CCCCC3)=O)=C2N1 LERWZBXJAOSNBN-DTQAZKPQSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- SVZORQBLCFZGBK-UHFFFAOYSA-N 1,3-bis(cyclohexylmethyl)urea Chemical compound C1CCCCC1CNC(=O)NCC1CCCCC1 SVZORQBLCFZGBK-UHFFFAOYSA-N 0.000 description 1
- MRLMAYKVVWSLGN-UHFFFAOYSA-N 2,6-dioxo-3,7-dihydropurine-8-carboxamide Chemical class N1C(=O)NC(=O)C2=C1N=C(C(=O)N)N2 MRLMAYKVVWSLGN-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- IUDNRKGPFWUYIC-UHFFFAOYSA-N 2-[2-(2-methoxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound COCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 IUDNRKGPFWUYIC-UHFFFAOYSA-N 0.000 description 1
- PDMAWCHFAXBCLZ-UHFFFAOYSA-N 2-formyl-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(C=O)=CC1=CC=CC=C1 PDMAWCHFAXBCLZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BTOJSYRZQZOMOK-UHFFFAOYSA-N 4-chloro-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(Cl)=C2C=C1 BTOJSYRZQZOMOK-UHFFFAOYSA-N 0.000 description 1
- SKYWUTJNPCCSDO-UHFFFAOYSA-N 6-amino-1,3-bis(cyclohexylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC2CCCCC2)C(N)=CC(=O)N1CC1CCCCC1 SKYWUTJNPCCSDO-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005024 alkenyl aryl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- XQPRBTXUXXVTKB-UHFFFAOYSA-M caesium iodide Chemical compound [I-].[Cs+] XQPRBTXUXXVTKB-UHFFFAOYSA-M 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- OZECDDHOAMNMQI-UHFFFAOYSA-H cerium(3+);trisulfate Chemical compound [Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OZECDDHOAMNMQI-UHFFFAOYSA-H 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical class F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- AVKNGPAMCBSNSO-UHFFFAOYSA-N cyclohexylmethanamine Chemical compound NCC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-N 0.000 description 1
- DZLLYADKCHLBMB-UHFFFAOYSA-N cyclohexylmethylurea Chemical compound NC(=O)NCC1CCCCC1 DZLLYADKCHLBMB-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 125000004524 naphthpyridyl group Chemical group C1(=CC=NC2=C1C1=CC=CC=C1C=C2)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9817623.3A GB9817623D0 (en) | 1998-08-13 | 1998-08-13 | Pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200101186B true ZA200101186B (en) | 2002-02-12 |
Family
ID=10837179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200101186A ZA200101186B (en) | 1998-08-13 | 2001-02-12 | Phenyl xanthine derivatives. |
Country Status (37)
Country | Link |
---|---|
US (3) | US6608069B1 (zh) |
EP (1) | EP1104422B1 (zh) |
JP (3) | JP3631961B2 (zh) |
KR (1) | KR20010085369A (zh) |
CN (2) | CN1149215C (zh) |
AP (1) | AP1408A (zh) |
AR (1) | AR020154A1 (zh) |
AT (1) | ATE259810T1 (zh) |
AU (1) | AU775819B2 (zh) |
BR (1) | BR9913020A (zh) |
CA (1) | CA2340350A1 (zh) |
CO (1) | CO5130007A1 (zh) |
DE (1) | DE69914921T2 (zh) |
DK (1) | DK1104422T3 (zh) |
EA (1) | EA004139B1 (zh) |
EE (1) | EE04721B1 (zh) |
ES (1) | ES2215399T3 (zh) |
GB (1) | GB9817623D0 (zh) |
HK (1) | HK1035195A1 (zh) |
HU (1) | HUP0103637A3 (zh) |
ID (1) | ID28723A (zh) |
IL (1) | IL141318A0 (zh) |
IS (1) | IS5843A (zh) |
MA (1) | MA26673A1 (zh) |
MY (1) | MY133393A (zh) |
NO (1) | NO20010715L (zh) |
NZ (1) | NZ509778A (zh) |
PE (1) | PE20000952A1 (zh) |
PL (1) | PL346055A1 (zh) |
PT (1) | PT1104422E (zh) |
SI (1) | SI1104422T1 (zh) |
SK (1) | SK2222001A3 (zh) |
TR (1) | TR200100448T2 (zh) |
TW (1) | TWI224598B (zh) |
WO (1) | WO2000009507A1 (zh) |
YU (1) | YU11601A (zh) |
ZA (1) | ZA200101186B (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9703044D0 (en) | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
CA2428753C (en) * | 2000-11-17 | 2013-05-21 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
EP1372661B1 (en) * | 2001-02-28 | 2006-05-17 | SmithKline Beecham Corporation | Glycol derivatves of xanthines for treating irritable bowel syndrome |
WO2003017964A1 (en) | 2001-08-24 | 2003-03-06 | Unilever N.V. | Oral composition comprising an alkylhydroxybenzoate |
IL161867A0 (en) | 2001-11-09 | 2005-11-20 | Cv Therapeutics Inc | A2b adenosine receptor antagonists |
US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7125993B2 (en) | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US20040072848A1 (en) * | 2002-02-26 | 2004-04-15 | Huber Brian E | Methods of treating irritable bowel syndrome and functional dyspepsia |
JP4491344B2 (ja) | 2002-06-17 | 2010-06-30 | グラクソ グループ リミテッド | 肝x受容体アゴニストとしてのプリン誘導体 |
CN1894250B (zh) * | 2003-08-25 | 2010-06-09 | PGx健康有限责任公司 | 取代的8-杂芳基黄嘌呤 |
GB0324086D0 (en) * | 2003-10-14 | 2003-11-19 | Glaxo Group Ltd | Process for preparing a co-precipitate of a non-crystalline solid drug substance |
WO2006004903A2 (en) * | 2004-06-28 | 2006-01-12 | Atherogenics, Inc. | 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
WO2006091936A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
WO2009140517A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
WO2009140519A1 (en) * | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
US8318728B2 (en) | 2008-05-14 | 2012-11-27 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
RU2509081C2 (ru) * | 2008-05-30 | 2014-03-10 | Дженентек, Инк. | Пуриновые соединения, ингибирующие рi3к, и способы применения |
CN102260260B (zh) * | 2010-05-24 | 2014-08-06 | 中国科学院上海药物研究所 | 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途 |
CN102993203B (zh) * | 2011-09-09 | 2015-11-25 | 温州医学院 | 8-苯基黄嘌呤类衍生物的制备及应用 |
US9502952B2 (en) | 2012-10-12 | 2016-11-22 | Persimmon Technologies, Corp. | Hybrid motor |
CN105358154A (zh) | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
WO2014182950A1 (en) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
EP2994138A4 (en) * | 2013-05-10 | 2016-12-28 | Nimbus Apollo Inc | ACC-HEMMER AND USES THEREOF |
WO2014182951A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
EP4389749A1 (en) * | 2022-12-20 | 2024-06-26 | invIOs GmbH | Substituted 3,7-dihydro-1h-purine-2,6-diones and use thereof |
WO2024133605A1 (en) | 2022-12-20 | 2024-06-27 | Invios Gmbh | Substituted 3,7-dihydro-1 h-purine-2,6-diones and use thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4442125A (en) * | 1978-06-26 | 1984-04-10 | Oxford Hill, Ltd. | Process for detaching or preventing attachment of microorganisms to a surface |
GB8510758D0 (en) | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
US4968672A (en) * | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
US5015647A (en) | 1987-04-24 | 1991-05-14 | Burroughs Wellcome Co. | Method for treating viral infections |
GB8826595D0 (en) | 1988-11-14 | 1988-12-21 | Beecham Wuelfing Gmbh & Co Kg | Active compounds |
GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
NZ240644A (en) | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
GB9210839D0 (en) | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
TW252044B (zh) | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
JP2613355B2 (ja) | 1992-09-28 | 1997-05-28 | 協和醗酵工業株式会社 | パーキンソン氏病治療剤 |
WO1995013094A1 (en) * | 1993-11-10 | 1995-05-18 | Bristol-Myers Squibb Company | Treatment of bacterially-induced inflammatory diseases |
US5395831A (en) | 1994-04-08 | 1995-03-07 | American Home Products Corporation | Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone |
GB9415529D0 (en) * | 1994-08-01 | 1994-09-21 | Wellcome Found | Phenyl xanthine derivatives |
DE19535504A1 (de) | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
AU2213697A (en) | 1996-03-18 | 1997-10-10 | Medical Science Systems, Inc. | A method for periodontal disease treatment |
DK0812844T3 (da) | 1996-06-07 | 2003-02-17 | Hoechst Ag | Anvendelse af theophyllinderivater til behandling og profylakse af choktilstande, nye xanthinforbindelser og fremgangsmåder til deres fremstilling |
GB9703044D0 (en) | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
US6096707A (en) * | 1997-07-11 | 2000-08-01 | Biotie Therapies Ltd. | Integrin binding peptide and use thereof |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
AU2640999A (en) | 1998-02-26 | 1999-09-15 | Zenyaku Kogyo Kabushiki Kaisha | 1-azaindolizine derivatives |
GB9817623D0 (en) * | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
EP1246621A4 (en) | 1999-12-23 | 2004-11-24 | Nitromed Inc | NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE |
US20020006915A1 (en) * | 2000-02-15 | 2002-01-17 | Mack Strong Vivian E. | Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation |
US6751206B1 (en) | 2000-06-29 | 2004-06-15 | Qualcomm Incorporated | Method and apparatus for beam switching in a wireless communication system |
-
1998
- 1998-08-13 GB GBGB9817623.3A patent/GB9817623D0/en not_active Ceased
-
1999
- 1999-08-10 CO CO99050691A patent/CO5130007A1/es unknown
- 1999-08-10 AR ARP990103999A patent/AR020154A1/es not_active Application Discontinuation
- 1999-08-11 EE EEP200100083A patent/EE04721B1/xx not_active IP Right Cessation
- 1999-08-11 BR BR9913020-3A patent/BR9913020A/pt not_active IP Right Cessation
- 1999-08-11 MA MA25728A patent/MA26673A1/fr unknown
- 1999-08-11 CA CA002340350A patent/CA2340350A1/en not_active Abandoned
- 1999-08-11 AU AU57323/99A patent/AU775819B2/en not_active Ceased
- 1999-08-11 EP EP99944358A patent/EP1104422B1/en not_active Expired - Lifetime
- 1999-08-11 KR KR1020017001799A patent/KR20010085369A/ko active IP Right Grant
- 1999-08-11 MY MYPI99003429A patent/MY133393A/en unknown
- 1999-08-11 ES ES99944358T patent/ES2215399T3/es not_active Expired - Lifetime
- 1999-08-11 HU HU0103637A patent/HUP0103637A3/hu unknown
- 1999-08-11 JP JP2000564958A patent/JP3631961B2/ja not_active Expired - Fee Related
- 1999-08-11 EA EA200100127A patent/EA004139B1/ru unknown
- 1999-08-11 ID IDW20010591A patent/ID28723A/id unknown
- 1999-08-11 SI SI9930545T patent/SI1104422T1/xx unknown
- 1999-08-11 AT AT99944358T patent/ATE259810T1/de not_active IP Right Cessation
- 1999-08-11 AP APAP/P/2001/002071A patent/AP1408A/en active
- 1999-08-11 PT PT99944358T patent/PT1104422E/pt unknown
- 1999-08-11 YU YU11601A patent/YU11601A/sh unknown
- 1999-08-11 IL IL14131899A patent/IL141318A0/xx unknown
- 1999-08-11 PE PE1999000814A patent/PE20000952A1/es not_active Application Discontinuation
- 1999-08-11 DE DE69914921T patent/DE69914921T2/de not_active Expired - Fee Related
- 1999-08-11 CN CNB998119695A patent/CN1149215C/zh not_active Expired - Fee Related
- 1999-08-11 CN CNB031104673A patent/CN1251676C/zh not_active Expired - Fee Related
- 1999-08-11 US US09/762,559 patent/US6608069B1/en not_active Expired - Fee Related
- 1999-08-11 PL PL99346055A patent/PL346055A1/xx not_active Application Discontinuation
- 1999-08-11 NZ NZ509778A patent/NZ509778A/en unknown
- 1999-08-11 WO PCT/EP1999/005814 patent/WO2000009507A1/en active IP Right Grant
- 1999-08-11 TR TR2001/00448T patent/TR200100448T2/xx unknown
- 1999-08-11 SK SK222-2001A patent/SK2222001A3/sk unknown
- 1999-08-11 DK DK99944358T patent/DK1104422T3/da active
- 1999-08-12 TW TW088113815A patent/TWI224598B/zh not_active IP Right Cessation
-
2001
- 2001-02-09 IS IS5843A patent/IS5843A/is unknown
- 2001-02-12 NO NO20010715A patent/NO20010715L/no not_active Application Discontinuation
- 2001-02-12 ZA ZA200101186A patent/ZA200101186B/en unknown
- 2001-08-22 HK HK01105939A patent/HK1035195A1/xx not_active IP Right Cessation
-
2002
- 2002-03-26 US US10/106,772 patent/US6770267B2/en not_active Expired - Fee Related
-
2003
- 2003-02-03 US US10/357,751 patent/US20040034020A1/en not_active Abandoned
- 2003-06-09 JP JP2003164252A patent/JP2004137251A/ja not_active Withdrawn
- 2003-11-25 JP JP2003394308A patent/JP2004115534A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200101186B (en) | Phenyl xanthine derivatives. | |
CA2094270C (en) | Xanthine derivatives | |
JPH03173889A (ja) | キサンチン誘導体 | |
EP0775141A1 (en) | Phenyl xanthine derivatives | |
JP2613352B2 (ja) | パーキンソン病治療剤 | |
JPH03204880A (ja) | 縮合プリン誘導体 | |
AP1000A (en) | Substituted(1,3-Bis(cyclohexylmethyl)-1,2,3,6- tetrahydro-2, 6-dioxo-9h-purin-8-y1) phenyl derivatives, thier preparation and their use in the treatment of inflammatory conditions and immune disorders. | |
US20090163491A1 (en) | Substituted 8-[6-amino-3pyridyl]xanthines | |
JPH05222045A (ja) | アゾール誘導体 | |
MXPA01001632A (en) | Phenyl yanthine derivatives | |
CZ2001552A3 (cs) | Fenylxanthinové deriváty | |
JPH03264585A (ja) | イミダゾキノロン誘導体 | |
MXPA99007508A (en) | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders |